Skip to main content

GLP-1 Agonist Obesity Deal Benchmarks 2026

Median Upfront
$935M
Range: $509M - $1.5B
Total Deal Value
$4.5B
Range: $2.9B - $6.1B
Royalty Rate
16.1% - 29.5%
Tiered up to 33.5%
Dev Milestones
$647M
Range: $438M - $833M
Model Your Deal

Market Analysis

GLP-1 receptor agonists have become the defining drug class of the decade. Semaglutide (Wegovy/Ozempic) generated $20B+ in annual revenue by 2025, making it the fastest drug to that milestone in pharma history. Tirzepatide (Mounjaro/Zepbound) achieved 22.5% weight loss in clinical trials, approaching bariatric surgery efficacy without the surgical risk.

Phase 2 GLP-1 agonist licensing deals for obesity carry median upfront payments of $935M (range $509M - $1.5B), with total deal values reaching $4.5B. The CSPC/AstraZeneca deal at $18.5B headline value and Carmot/Roche acquisition at $2.7B set the high-water marks for the category.

Oral GLP-1 formulations command significant premiums: $1.1B upfront vs $935M for injectables. The oral convenience advantage drives patient preference, primary care adoption, and payer formulary access — making oral GLP-1 assets the most sought-after in biopharma.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How much are GLP-1 obesity deals worth in 2026?
Phase 2 injectable GLP-1 deals average $4.5B total deal value with $935M upfront. Oral GLP-1 assets command 20-30% premiums, averaging $5.1B total value.
What royalty rates do GLP-1 obesity deals command?
GLP-1 obesity royalties range from 16.1%-29.5% base tier, escalating to 33.5% at peak sales. The $100B+ projected obesity market drives aggressive tiered royalty structures.
How do oral GLP-1 deals compare to injectable GLP-1 deals?
Oral GLP-1 deals command 20-30% premiums over injectable equivalents. Oral formulations average $1.1B upfront vs $935M for injectables, reflecting the oral convenience advantage for patient adherence and primary care adoption.

Related Benchmarks

Metabolic & Obesity Overview

View

Dual Incretin Deal Benchmarks

View

NASH/MASH Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating